SV2 PET Imaging with [11C]APP311

Launched by YALE UNIVERSITY · Jun 19, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique using a special substance called \[11C\]APP311 to look at the brain's SV2A levels in people with schizophrenia, other psychotic disorders, cannabis use disorder, and healthy individuals. The goal is to understand how this tracer works in both healthy aging and those with neuropsychiatric conditions. The trial is currently looking for participants aged 18 to 65 who are willing to provide informed consent to take part.

If you decide to participate, you will undergo imaging scans, which are painless and similar to a regular MRI, but there are some important things to keep in mind. You should not have any metal implants or issues with claustrophobia since they may prevent you from undergoing the scan. Additionally, you need to have completed at least 12 years of education. This trial is a chance to contribute to research that may improve our understanding of brain health in both healthy individuals and those with certain disorders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willing and able to give voluntary written informed consent
• • Male and Female subjects, age 18 to 65 years, inclusive
• Exclusion Criteria:
• • MRI metal exclusions and claustrophobia.
• • Education completed is less than 12 years